MAS1 Antibody

What is MAS1 and what role does it play in biological systems?

MAS1 is a proto-oncogene that encodes a G protein-coupled receptor (GPCR) with a molecular mass of approximately 37.5 kDa. It functions as a receptor for angiotensin-(1-7) and preferentially couples to the Gq protein, activating the phospholipase C signaling pathway . MAS1 plays crucial roles in:

• Acting as a functional antagonist of AGTR1 (angiotensin-2 type 1 receptor)

• Mediating anti-inflammatory responses and tissue protection

• Contributing to vascular development and angiogenesis

• Regulating vasodilation and blood pressure

• Maintaining tight junction integrity in epithelial barriers

For proper investigation of MAS1 function, researchers should consider using multiple detection methods beyond antibody-based approaches, including gene expression analysis via RT-PCR and functional assays specific to GPCR signaling.

What are the most effective applications for MAS1 antibodies in research?

MAS1 antibodies can be utilized across multiple experimental platforms:

When designing MAS1 antibody experiments, researchers should:

• Include appropriate positive controls (tissues known to express MAS1, such as kidney)

• Implement negative controls (MAS1 knockout tissues/cells when available)

• Validate results using complementary techniques (RT-PCR, functional assays)

• Optimize protocol conditions for each specific application and tissue type

How can researchers validate the specificity of MAS1 antibodies?

Validation of MAS1 antibody specificity is critical for reliable research outcomes. Multiple complementary approaches should be used:

• Genetic validation: Compare antibody staining between wild-type and MAS1 knockout/knockdown models

  • siRNA knockdown validation as demonstrated in inflammation studies

  • Transfection with MAS1 overexpression plasmids as positive controls

• Peptide competition assays: Pre-incubation of antibody with immunizing peptide should abolish specific signal

• Multiple antibody validation: Use antibodies targeting different epitopes of MAS1

  • Compare antibodies recognizing N-terminal, middle region, and C-terminal domains

• Correlation with mRNA expression: Verify antibody signal corresponds with MAS1 transcript levels

  • As demonstrated in the study overexpressing Mas1 in EpH4 EV cells, where Western blot results aligned with qPCR data

• Mass spectrometry verification: For immunoprecipitation experiments, confirm pulled-down proteins by MS/MS analysis

For reliable results, researchers should document all validation steps performed and include these details in publications.

What are the optimal protocols for using MAS1 antibodies in inflammation research?

MAS1 has significant anti-inflammatory properties, making MAS1 antibodies valuable tools in inflammation research. Based on recent studies:

Recommended Protocol for Cell Culture Models:

• Cell line selection: Mouse mammary epithelial cells (EpH4 EV) have been successfully used for MAS1-related inflammation studies

• Inflammation induction: LPS treatment (optimal concentration determined by cell viability assays) for 9 hours establishes a reliable inflammatory model

• MAS1 manipulation approaches:

  • Overexpression: Transfection with eukaryotic expression vectors (e.g., pVAX1-MAS1)

  • Silencing: siRNA treatment (test multiple sequences for optimal silencing efficiency)

• Readout parameters:

  • Pro-inflammatory cytokines: IL-1β, IL-6, TNF-α (detected by Western blot)

  • Inflammatory mediators: iNOS

  • Signaling pathway activation: NF-κB (p65 phosphorylation)

  • Tight junction proteins: ZO-1, occludin, Claudin-3

Data Analysis Considerations:

• Normalization to housekeeping genes/proteins is essential

• Statistical comparisons between control, inflammation model, and MAS1 manipulation conditions

• Dose-response relationships for both inflammatory stimuli and MAS1 modulators

Research has demonstrated that MAS1 overexpression significantly reverses LPS-induced upregulation of inflammatory mediators, while MAS1 silencing exacerbates inflammatory responses , suggesting therapeutic potential for MAS1 targeting in inflammatory conditions.

How can MAS1 antibodies be utilized to investigate receptor signaling mechanisms?

MAS1 receptor signaling is complex and involves multiple downstream pathways. MAS1 antibodies can be employed to elucidate these mechanisms:

Co-immunoprecipitation Protocol for MAS1 Signaling Partners:

• Cell preparation: Use cells with endogenous or overexpressed MAS1

• Stimulation: Treat with angiotensin-(1-7) to activate receptor signaling

• Lysis: Employ cryolysis for membrane protein extraction

• Immunoprecipitation: Use validated MAS1 antibodies (confirm epitope is intracellular)

• Complex verification: Immunoblotting for MAS1 and suspected interacting proteins

• Advanced analysis: Mass spectrometry (MS/MS) of immunoprecipitated complexes

Key MAS1 Signaling Pathways Identified:

• Rho Family GTPases

• Phosphatidylinositol 3-kinase

• Protein kinase D1

• MAPK pathways including ERK1/2 and p38MAPK

Researchers investigating MAS1 signaling should consider:

• Time-course experiments to capture transient signaling events

• Pharmacological inhibitors of specific pathway components

• Phosphorylation-specific antibodies for downstream effectors

• Combined approaches using both antibody-based detection and functional readouts

According to published research, antagonism of ERK1/2 and p38MAPK signaling inhibits endothelial tube formation and vasodilation when stimulated with angiotensin-(1-7), confirming their role in MAS1-mediated vascular effects .

What considerations are important when using MAS1 antibodies in vascular development research?

MAS1 plays significant roles in vascular development, particularly in angiogenesis and retinal vascular formation. When using MAS1 antibodies in this research context:

Experimental Design Recommendations:

• Model selection:

  • In vitro: Rat microvascular endothelial cells (RMVECs) for tube formation assays

  • In vivo: Developing retina in wild-type vs. Mas1-deficient (Mas1−/−) mice

• Key parameters to measure:

  • Progression of vascular front

  • Filopodia sprouting

  • Microglia positioning at vascular front

  • Expression of angiogenic markers (Notch1, Delta-like ligand 4, Jagged1)

• Environmental conditions:

  • Hypoxia significantly upregulates Mas1 in microglia in developing retina

  • Consider oxygen concentration as a critical experimental variable

• Methodological approaches:

  • Whole-mount retinal immunostaining with MAS1 antibodies

  • Co-staining with microglia markers to assess cellular localization

  • Confocal microscopy for detailed visualization of vascular structures

Research has demonstrated that Mas1-deficient mice show impaired vascular development linked to reduced numbers of microglia at the developing retinal vasculature front, indicating a crucial role for MAS1 in coordinating microglia positioning and vascular development .

How should researchers approach MAS1 antibody selection for autoimmunity studies?

MAS1 has emerging relevance in autoimmune conditions, with anti-MAS1 autoantibodies detected in certain patient populations:

Selection Criteria for Autoimmunity Research:

• Epitope considerations:

  • Extracellular domain-targeting antibodies are preferable for detecting surface-expressed MAS1

  • Consider antibodies that won't compete with potential autoantibodies binding to MAS1

• Detection systems:

  • ELISA-based systems for quantifying anti-MAS1 autoantibodies in patient sera

  • Flow cytometry for cell-surface detection of MAS1 in patient-derived samples

• Validation for autoimmunity studies:

  • Use sera from confirmed autoimmune patients as positive controls

  • Include competitive binding assays to confirm specificity

  • Consider cross-reactivity with other GPCRs when interpreting results

Recent research has identified anti-MAS1 autoantibodies in post-acute COVID vaccination syndrome (PACVS), with specific symptom associations such as widespread burning sensation . This suggests MAS1 autoantibodies may serve as potential biomarkers for certain autoimmune conditions.

How can researchers address inconsistent results when using MAS1 antibodies?

Inconsistent results with MAS1 antibodies may stem from several factors:

Common Issues and Solutions:

Specific Protocol Optimization:

• For Western blotting:

  • Use RIPA buffer with protease inhibitors for efficient extraction

  • Predicted band size for MAS1: 37-42 kDa

  • Consider gradient gels for better resolution

• For immunohistochemistry:

  • Optimize fixation conditions (over-fixation can mask epitopes)

  • Use antigen retrieval methods appropriate for GPCR detection

  • Test antibody dilution ranges from 1:50-1:200

• For cell-based assays:

  • Consider receptor internalization following ligand exposure

  • Include time-course experiments to capture dynamic expression

When transitioning between applications (e.g., from WB to IHC), complete reoptimization is necessary for reliable results.

What are the best approaches for quantifying MAS1 receptor expression levels?

Accurate quantification of MAS1 receptor levels requires complementary approaches:

Protein-Level Quantification:

• Western blot densitometry:

  • Standardize loading with housekeeping proteins

  • Use calibration curves with recombinant standards when available

  • Apply appropriate statistical analysis for replicate measurements

• Flow cytometry:

  • Suitable for cell-surface MAS1 quantification

  • Compare mean fluorescence intensity (MFI) across samples

  • Include saturation binding controls

• ELISA:

  • Develop sandwich ELISA using antibodies targeting different epitopes

  • Include standard curves with recombinant MAS1 protein

  • Validate sample preparation methods for consistency

mRNA-Level Quantification:

• Quantitative RT-PCR:

  • Design primers spanning exon-exon junctions

  • Normalize to appropriate reference genes (validate stability)

  • Example primer design based on mouse Mas1 gene (GenBank: NM_008552.5)

• Digital PCR:

  • Provides absolute quantification without standard curves

  • Reduced sensitivity to PCR inhibitors in complex samples

• RNA-Seq:

  • Enables transcriptome-wide analysis and splicing variants

  • Requires appropriate bioinformatic analysis pipeline

Correlation Analysis:

• Researchers should confirm correlation between protein and mRNA levels

• Discrepancies may indicate post-transcriptional regulation

In published research, successful quantification of Mas1 overexpression was achieved by combining qPCR for transcript abundance and Western blot for protein levels, providing complementary validation .

What controls are essential when using MAS1 antibodies in complex experimental systems?

Rigorous controls are critical for MAS1 antibody experiments, particularly in complex systems:

Essential Controls for MAS1 Antibody Experiments:

• Positive controls:

  • Cell lines with confirmed MAS1 expression (HEK293T, NIH3T3, PC12)

  • Tissues with known high expression (kidney for Mas1 gene amplification)

  • Recombinant MAS1 protein or MAS1-overexpressing constructs

• Negative controls:

  • Primary antibody omission

  • Isotype controls (same species/isotype as primary antibody)

  • MAS1 knockout/knockdown samples when available

  • Pre-immune serum for polyclonal antibodies

• Specificity controls:

  • Peptide competition/blocking experiments

  • Multiple antibodies targeting different epitopes

  • siRNA validation (demonstrated effective silencing with siRNA-2 treatment)

• Technical controls:

  • Loading controls for Western blots (housekeeping proteins)

  • Endogenous peroxidase blocking for IHC

  • Autofluorescence controls for IF

• Biological reference points:

  • Comparison with MAS1 mRNA expression patterns

  • Correlation with functional responses to MAS1 ligands

  • Consideration of species differences in MAS1 sequence and expression

For experimental manipulations of MAS1, researchers should implement appropriate controls:

• For overexpression: empty vector controls (e.g., pVAX1 control group)

• For siRNA: non-targeting siRNA controls

• For drug treatments: vehicle controls

How can MAS1 antibodies support therapeutic antibody development research?

MAS1 antibodies can provide valuable insights for therapeutic antibody development:

Applications in Therapeutic Development:

• Target validation:

  • Confirm MAS1 expression in disease-relevant tissues

  • Correlate expression with pathophysiological processes

  • Assess accessibility of epitopes in native conformations

• Antibody screening platforms:

  • Competition assays with known MAS1 ligands

  • Epitope mapping to identify functional binding sites

  • Cross-reactivity assessment across species for preclinical translation

• Functional characterization:

  • Monitoring receptor internalization following antibody binding

  • Assessing pathway activation/inhibition

  • Evaluating effects on receptor dimerization

The development of therapeutic antibodies remains time and cost-intensive, but machine learning approaches have shown promise in optimizing antibody design, achieving up to 28.7-fold improvement in binding compared to traditional directed evolution approaches . These methods could potentially be applied to MAS1-targeting therapeutics.

What are the considerations for using MAS1 antibodies in immunotherapy research?

MAS1 has emerging relevance in immunotherapy, particularly in relation to its immunomodulatory properties:

MAS1 in Immunotherapy Research:

• MAS-1 as an adjuvant:

  • MAS-1 adjuvant emulsion demonstrates immunomodulatory properties

  • Promotes Th2 and regulatory immune responses in autoimmune disease models

  • Can be used alone or as part of antigen-specific immunotherapy

• Experimental design considerations:

  • Include time-course studies (MAS-1 adjuvant effects persist through 52 weeks in mouse models)

  • Measure multiple immune parameters (IL-10, IL-2, FoxP3+ T cells)

  • Assess antibody isotype profiles (IgG1, IgG2b for Th2 responses)

• Disease models:

  • Type 1 diabetes (NOD mice) shows significant response to MAS-1 adjuvant therapy

  • 60-73% of mice remain diabetes-free at 35 weeks with MAS-1-based treatments

  • Consider application to other autoimmune conditions

• Mechanistic investigations:

  • Use MAS1 antibodies to track receptor expression in immune cell populations

  • Monitor changes in receptor levels following immunotherapy

  • Correlate with functional immune parameters

Research demonstrates that MAS-1 adjuvant induces higher levels of IL-10-positive T cells, suggesting activation of regulatory mechanisms that may contribute to its therapeutic effects in autoimmune conditions .

How should researchers interpret contradictory findings in MAS1 antibody-based experiments?

Contradictory results with MAS1 antibodies may emerge due to biological complexity or technical factors:

Approach to Resolving Contradictions:

• Biological variables to consider:

  • Cell/tissue-specific MAS1 expression patterns

  • Receptor internalization and trafficking dynamics

  • Post-translational modifications affecting epitope accessibility

  • Context-dependent signaling (different pathways in different cell types)

  • Species differences in MAS1 structure and function

• Technical factors to evaluate:

  • Antibody specificity validation methods used

  • Epitope locations of different antibodies

  • Detection methods and sensitivity thresholds

  • Sample preparation differences

  • Quantification approaches

• Experimental design factors:

  • Timing of measurements (acute vs. chronic responses)

  • Experimental conditions affecting MAS1 expression

  • In vitro vs. in vivo context differences

• Resolution strategies:

  • Employ multiple antibodies targeting different epitopes

  • Use complementary non-antibody detection methods

  • Perform genetic manipulation (overexpression/knockdown) to confirm findings

  • Collaborate with other laboratories to replicate findings

When interpreting contradictory findings, researchers should consider the biological complexity of MAS1 signaling and its dual roles in different contexts. For example, while MAS1 shows anti-inflammatory properties in some systems , it may have different effects depending on the tissue microenvironment or disease state.

What emerging technologies are enhancing MAS1 antibody research?

Several cutting-edge technologies are advancing MAS1 antibody applications:

Emerging Technologies:

• Single-cell analysis:

  • Single-cell RNA-seq to correlate MAS1 expression with cellular phenotypes

  • Single-cell proteomics for protein-level characterization

  • Spatial transcriptomics to map MAS1 expression in tissue context

• Advanced imaging approaches:

  • Super-resolution microscopy for nanoscale localization of MAS1

  • Live-cell imaging to track receptor dynamics

  • Multiplexed imaging to assess MAS1 colocalization with signaling partners

• Antibody engineering:

  • Machine learning optimization of antibody properties (demonstrated 28.7-fold improvement in binding)

  • Development of nanobodies or single-chain variable fragments (scFvs) for improved tissue penetration

  • Bispecific antibodies targeting MAS1 and relevant pathway components

• Structural biology integration:

  • Cryo-EM studies of MAS1 in complex with antibodies

  • Molecular dynamics simulations to predict antibody-epitope interactions

  • Structure-based antibody design and optimization

• In silico approaches:

  • Virtual screening for novel MAS1-targeting compounds

  • Epitope prediction algorithms for antibody design

  • Systems biology modeling of MAS1 signaling networks

Research utilizing machine learning approaches for antibody design has demonstrated that 99% of designed scFvs in successful libraries show improvements over initial candidates , suggesting similar approaches could enhance MAS1-targeting antibody development.

How can researchers transition from in vitro to in vivo studies with MAS1 antibodies?

Successful translation from in vitro to in vivo MAS1 research requires careful planning:

Translation Strategy:

• Antibody validation for in vivo use:

  • Confirm specificity in relevant species

  • Evaluate tissue penetration capabilities

  • Assess half-life and biodistribution

  • Test for immunogenicity in target species

• Model selection considerations:

  • Mas1-deficient (Mas1−/−) mice for loss-of-function studies

  • Transgenic models with tissue-specific MAS1 expression

  • Disease models relevant to MAS1 function (inflammation, vascular disorders, autoimmunity)

• Experimental design adaptations:

  • Dosing and timing optimizations for in vivo contexts

  • Route of administration considerations

  • Sample collection planning for multi-parameter analysis

  • Long-term studies to capture chronic effects (up to 52 weeks in some models)

• Complementary approaches:

  • Combine antibody-based detection with functional readouts

  • Integrate imaging approaches (MRI, PET) with ex vivo analyses

  • Correlate tissue-specific findings with systemic parameters

Researchers should note limitations observed in previous studies - for example, one study demonstrated the role of MAS1 in inflammatory injury of mammary epithelial cells through in vitro approaches but acknowledged the need for in vivo validation in various mastitis models .